China Meheco subsidiary obtains drug registration certificate

China Meheco (SSE:600056) announced today that its wholly-owned subsidiary, Tianfang Pharmaceutical, has been granted a drug registration certificate from the National Medical Products Administration for Clopidogrel Bisulfate Tablets. Clopidogrel Bisulfate is a platelet inhibitor primarily used for the secondary prevention of atherothrombotic events in patients with recent myocardial infarction, ischemic stroke, or established peripheral arterial disease. The National Medical Products Administration accepted the registration application in January 2024. As of the announcement date, Tianfang Pharmaceutical has invested approximately CNY 19.54 million in the drug. According to a query of the database on menet.com.cn, the domestic sales of Clopidogrel Bisulfate Tablets in the domestic market were approximately CNY 4.924 billion in 2023 and CNY 5.376 billion in 2024. China Meheco cautioned investors about potential risks, including uncertainty surrounding sales performance due to factors such as national policies and market environment.